HRV14 VP1 Specific Neutra™ Antibody Products

Are you currently facing challenges in antibody development for respiratory viruses, such as cross-reactivity issues or low neutralization efficiency against specific serotypes? Our HRV14 VP1 Specific Neutra™ Antibody Products help you obtain high-quality, high-specificity research tools to streamline your vaccine and antiviral studies through advanced recombinant DNA technology and precision epitope mapping of the immunodominant VP1 capsid protein.

Introduction of HRV14 VP1

Human Rhinovirus 14 (HRV14) is a member of the Picornaviridae family and represents one of the most studied serotypes in the "major group" of rhinoviruses. These viruses are the primary etiologic agents of the common cold, but they also have significant clinical impact as triggers for exacerbations of asthma and chronic obstructive pulmonary disease (COPD).

Structure and Function of VP1

The HRV14 capsid is an icosahedral shell composed of 60 copies each of four structural proteins: VP1, VP2, VP3, and VP4. VP1 is the most exposed surface protein and plays a critical role in viral pathogenesis. It contains a deep surface depression known as the "canyon," which serves as the binding site for the cellular receptor, Intercellular Adhesion Molecule-1 (ICAM-1).

Fig.1 Human rhinovirus genomic organization, virion structure, and species.¹

Pathogenesis and Signaling

Viral entry is initiated when the VP1 canyon engages ICAM-1, triggering a conformational change (often described as "breathing") that leads to the release of VP4 and the externalization of the N-terminus of VP1. This process forms a pore in the endosomal membrane, allowing the translocation of the viral (+)ssRNA genome into the host cytoplasm.

Clinical Impact

While HRV14 infections are often self-limiting, the high density of interfacial residues in the VP1-VP2-VP3 complex makes the capsid a prime target for drug discovery. Research emphasizes that targeting VP1 can effectively inhibit viral uncoating and attachment, making it the focal point for modern immunotherapy and vaccine design.

Applications of anti-HRV14 VP1 Neutralizing Antibodies

Antibodies targeting the VP1 protein of HRV14 are indispensable tools in both basic virology and clinical development:

• Inhibition Assays: Neutralizing antibodies are used to block the interaction between the viral capsid and the ICAM-1 receptor, essential for screening the potency of new antiviral candidates.
• Vaccine Research: As VP1 is immunodominant, these antibodies serve as positive controls in immunogenicity studies to verify the folding and antigenic integrity of recombinant vaccine antigens.
• Mechanism of Action Studies: High-resolution structural studies (Cryo-EM) utilize anti-VP1 Fabs to understand how antibody binding stabilizes or destabilizes the capsid, preventing genome release.
• Diagnostic Development: VP1-specific antibodies allow for the precise detection of HRV14 in clinical samples and infected cell cultures (e.g., HeLa cells) without cross-reacting with unrelated respiratory viruses.

Our anti-HRV14 VP1 Neutralizing Antibodies

Creative Biolabs offers a robust portfolio of HRV14 VP1 Specific Neutra™ Antibody Products characterized by their superior specificity and purity.

• Monoclonal Excellence: Our flagship clones (e.g., SAA series) are produced via recombinant systems, ensuring batch-to-batch consistency and high purity (>95% by SDS-PAGE).
• Epitope Specificity: We offer antibodies targeting the B-C and H-I loops of VP1, which are known hot-spots for viral neutralization.
• Multiple Formats: Available as full IgG, Fab fragments, or conjugated to biotin/FITC for various experimental needs.
• Low Endotoxin Levels: All products are processed to ensure minimal endotoxin content, making them suitable for in vitro functional assays and in vivo animal models.

At Creative Biolabs, we combine two decades of biopharmaceutical expertise to deliver neutralizing antibodies that meet the rigorous demands of modern drug discovery. Our HRV14 VP1 specific products are designed to overcome the common pitfalls of viral research, providing clarity in an otherwise complex antigenic landscape.

To discuss your specific project requirements or to receive a custom quote for bulk quantities, please reach out to our technical support team. We are committed to providing the scientific depth and high-quality reagents needed to bring your therapeutic candidates to the clinic faster.

Contact Our Team for More Information and to Discuss Your Project

Reference

1. Stobart, Christopher C et al. "Rhinovirus Biology, Antigenic Diversity, and Advancements in the Design of a Human Rhinovirus Vaccine." Frontiers in microbiology vol. 8 2412. 5 Dec. 2017, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fmicb.2017.02412